Activation syndrome
Activation syndrome is a form of stimulation (sometimes suicidal) or agitation that has been observed in association with some psychoactive drugs.[1] A causative role has not been established.[2] Pfizer has denied that sertraline can cause such effects.[3][4]
Treatment
Serotonin reuptake inhibitors (SSRI) have been used in the induction of an "activation syndrome" (restlessness, labiality, etc.). The syndrome generally represents a state change that encourages suicidal tendencies in people under age 25 during the initial weeks of treatment.[5] SSRI-induced activation syndrome is well-accepted by clinicians.[6] Evidence reveal that jitteriness/anxiety syndrome predicts an improved prognosis (level D). Further, people with panic disorder with the syndrome may tolerate doses of tricyclic antidepressants without affecting outcome level D.[7] Activation syndrome resolves within hours of discontinuing the serotonergic agent and initiating care. However, drugs with half-lives may cause symptoms to persist. Monoamine oxidase inhibitors (MAOIs) carry the risk, and symptoms persist for several days.[8]
References
- ↑ http://www.breggin.com/recentregulatory.pbreggin.2006.pdf
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ http://www.healyprozac.com/AcademicStalking/Post%203%20-%20Pfizer%20letter%20re%20Healy.pdf
- ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2010-12-23. Retrieved 2010-06-14.
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ Reid JM, Storch EA, Murphy TK, Bodzin D, Mutch PJ, Lehmkuhl H, Aman M, Goodman WK (2010). "Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile". Child Youth Care Forum. 39: 113–124. doi:10.1007/s10566-010-9095-5. PMC 2867356. PMID 20473344.
- ↑ http://bjp.rcpsych.org/content/194/6/483.full
- ↑ http://www.uptodate.com/contents/serotonin-syndrome